No Detail Found!

Development, in vitro characterization and comparative pharmacokinetic evaluation of novel controlled release matrix tablets vs. Conventional tablets of olanzapine in healthy human volunteers.

Author(s)
Samiullah Department of Pharmacy, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
Fazal Subhan Department of Pharmacy, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
Syed Muhammad Sultan Department of Psychiatry, Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan
Amir Badshah Department of Pharmacy, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
Aziz Muhammad Department of Psychiatry, Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan
Khalid Rauf Department of Pharmaceutical Sciences, COMSATS Institute of Information Technology, Abbottabad, KPK, Pakistan
Gowhar Ali Department of Pharmacy, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
Abstract
Antipsychotics (including Olanzapine) are frequently associated with some agonizing adverse effects that are based on their erratic bioavailability via conventional oral dosage form(s). This commonly leads to either non-compliance or complete withdrawal from medications by concerned patients. To optimize the release pattern of Olanzapine, it was formulated into controlled release (CR) matrix tablets by direct compression method using combinations of Methocel® K100 LV-CR and Ethocel® standard 7 premiums as polymeric choices. These formulations were classified as F-A, F-B, and F-C based on combinations of Methocel® and Ethocel® in variable proportions. Physicochemical characterizations and drug release kinetics assessment of F-C (30% Methocel® and 60% Ethocel®) vs F-A and F-B in various dissolution media using paddle method at 50 rpm, depicted pH- independent zero-order release kinetics for twenty four hours. Pharmacokinetic profile comparison of selected formulation (F-C) with conventional reference tablets was conducted by utilizing randomized, open-labeled, 2-period, single-dose study protocol with 2-week washout period in healthy human volunteers, using HPLC-ECD method for quantification of Olanzapine. Estimation of comparative tolerability by the volunteers was also performed by clinical assessment of severity of associated adverse effects of Olanzapine. As compare to conventional tablets CR matrix tablets exhibited significantly protracted Tmax and optimized Cmax values (P
Publication Details
Page(s) 948-955
DOI DOI not available
Published Journal: Journal of Chemical Society of Pakistan, Volume: 35, Issue: 3, Year: 2013

Request the full text from PASTIC

More from Journal of Chemical Society of Pakistan
0

Citations

0

Downloads

106

Views

Copyright ©  PASTIC National Center, Islamabad www.pastic.gov.pk